What can breast cancer molecular sub-classification add to conventional diagnostic tools?

Annals of Oncology

Volumn 18, Issue SUPPL. 9, 2007, Pages

  Andre F ^a   Domont, J ^a   Delaloge, S ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BRCA1 PROTEIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MOLECULAR MARKER; PROGESTERONE RECEPTOR; PROTEIN P53; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADJUVANT THERAPY; BREAST CANCER; CANCER CLASSIFICATION; CANCER RESISTANCE; CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG EFFICACY; GENE EXPRESSION PROFILING; GENE MUTATION; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MICROARRAY ANALYSIS; MOLECULAR GENETICS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; BREAST TUMOR; CLASSIFICATION; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MOLECULAR BIOLOGY; PATHOLOGY; REVIEW; SENSITIVITY AND SPECIFICITY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DIAGNOSTIC IMAGING; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR BIOLOGY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 36048932365     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm291     Document Type: Conference Paper

References (29)

1. Contesso G, Mouriesse H, Friedman S et al. The importance of histologic grade in long-term prognosis of breast cancer: A study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 1987; 5: 1378-1386.
2. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
3. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
4. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
5. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393-10398.
6. Pusztai L, Ayers M, Stec J et al. Gene expression profiles obtained from single passage fine needle aspirations (FNA) of breast cancer reliably identify prognostic/predictive markers such as estrogen (ER) and HER-2 receptor status and reveal large scale molecular differences between ER-negative and ER-positive tumors. Clin Cancer Res 2003; 9: 2406-2415.
7. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 1: 5678-5685.
8. Calza S, Hall P, Auer G et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 2006; 8: R34.
9. Winer E, Carey LA, Dowsett M et al. Beyond anatomic staging: Are we ready to take the leap to molecular classification? Educational book, American Society of Clinical Oncology 2005: 46-59.
10. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502.
11. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
12. Ribeiro-Silva A, Ramalho LN, Garcia SB et al. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: Further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 2005; 47: 458-466.
13. Abd El-Rehim DM, Ball G, Pinder SE et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005; 116: 340-350.
14. Hoch RV, Thompson DA, Baker RJ et al. GATA3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer 1999; 84: 122-128.
15. Foulkes WD, Stefansson IM, Chappuis PO et al. Germline BRCA1 mutations and a basal phenotype in breast cancer. J Natl Cancer Inst 2003; 95: 1482-1485.
16. Richardson AL, Wang ZC, De Nicolo A et al. X chromosomal abnormalities in basal-like breast cancer. Cancer Cell 2006; 9: 121-132.
17. Andre F, Conforti R, Tomasic G. Predictive values of estrogen receptor expression and molecular subclassification for the benefit of adjuvant anthracycline-based chemotherapy in two randomized trials. San Antonio Breast Cancer Symposium 2006; Abstract 1028.
18. Geisler S, Lonning PE, Aas T et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61: 2505-2512.
19. Bertheau P, Piassa F, Espie M et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002; 360: 852-854.
20. Troester MA, Hoadley KA, Sorlie T et al. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 2004; 64: 4218-4226.
21. Fedier A, Moawad A, Haller U et al. p53-deficient cells display increased sensitivity to anthracyclines after loss of the catalytic subunit of the DNA-dependent protein kinase. Int J Oncol 2003; 23: 1431-1437.
22. Di Leo A, Gancberg D, Larsimont D et al. HER-2 amplification and topoisomerase Ilalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002; 8: 1107-1116.
23. Andre F, Hatzis C, Anderson K. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007; 13: 2061-2067.
24. Moyano JV, Evans JR, Chen F et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006; 116: 261-270.
25. Oh DS, Troester MA, Usary J et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006; 24: 1656-1664.
26. Pritchard KI, Shepherd LE, O'Malley FP et al. National Cancer Institute of Canada Clinical Trials Group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354: 2103-2111.
27. Hayes DF, Thor A, Dressler L et al. HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. Vol 24 No. 18S (June 20 Supplement), 2006: 510.
28. Berry DA, Cirrincione G, Henderson IC et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295: 1658-1667.
29. Hu Z, Fan C, Oh DS et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7: 96.